FDA approves AstraZeneca treatment for cases reacting badly to vaccines

By Akshay Kedari  | Date: 2021-12-09

FDA approves AstraZeneca treatment for cases reacting badly to vaccines

The U.S. FDA has reportedly issued an emergency use authorization of synthetic AstraZeneca antibodies for the prevention of Covid-19 infections in people who have had a severe reaction to vaccines. This is the first time the U.S. health authority has granted emergency approval for such a purely preventative treatment.

According to the FDA, the drug Evusheld isn’t a replacement for vaccination in those for whom COVID-19 vaccination is advised and can only be used by patients with a weaker immune system or who are unable to be vaccinated due to medical reasons such as a severe allergic reaction. In such cases, the drug can be provided for people who are aged 12 or above.

For those unaware, Evusheld is a drug that combines two synthetic antibodies (tixagevimab and cilgavimab) and is administered as two consecutive intramuscular injections. These antibodies aid the immune system in combating the virus by attacking the virus's spike protein, which permits it to access and infect cells. 

As per a statement given by the FDA, it may be useful for pre-exposure protection for six months and cannot be given to someone who is already infected with the virus, though AstraZeneca is testing it for this purpose.

The drug is known to have possible side effects like allergic reactions, bleeding from the injection site, headaches, and lethargy.

The FDA's approval was based on a clinical trial that included unvaccinated adults over the age of 59, suffering from chronic diseases, or those who were at high risk of infection. The result showed that the therapy reduced the probability of developing COVID-19 by 77%.

In the United States, two antibody cocktails developed by Regeneron and Eli Lilly are presently approved for the prevention of infection, but only in those who have recently been exposed to the virus or who have a high risk of being exposed to the disease.

Source Credit:

https://www.ndtv.com/world-news/us-authorizes-astrazeneca-evusheld-drug-for-covid-treatment-in-some-cases-2643322

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Apple announces new accessibility features including ‘Personal Voice’

Apple announces new accessibility features including ‘Personal Voice’

By Akshay Kedari

America’s technology giant Apple reportedly announced that it will soon launch "Personal Voice" with a new set of accessibility features. This will allow iPhone and iPad users to make their devices speak in their own voice, allowing u...

Cop28 to emphasize on health issues related climate conditions

Cop28 to emphasize on health issues related climate conditions

By Akshay Kedari

According to reliable sources, the upcoming United Nations Climate Change Conference, to be held in November 2023, will be the flagbearer for conducting a meeting of the global health ministers discussing the consequences of climate crisis on public ...

Hyundai-Kia combined earnings to exceed Toyota in a rare occurrence

Hyundai-Kia combined earnings to exceed Toyota in a rare occurrence

By Akshay Kedari

As per the reports, South Korean automaker Kia Corp., along with its parent Hyundai Motor Company, are anticipated to outperform Toyota Motor Corp. in the Q1 earnings for the first time ever. The combined operating profits for Hyundai & Kia wa...

Meta continues mass layoff spree, cuts another 4,000 jobs this week

Meta continues mass layoff spree, cuts another 4,000 jobs this week

By Akshay Kedari

Silicon Valley tech giant, Meta Platforms Inc., formerly known as Facebook, is reportedly cutting another 4,000 jobs this week in another round of mass layoffs. The latest job cuts are a part of the 10,000 layoffs announced in March. The company i...

Stoke Space unveils tracking software for development of complex hardware

Stoke Space unveils tracking software for development of complex hardware

By Akshay Kedari

Stoke Space, a space launch company, has reportedly introduced a new software tool designed to allow hardware companies to monitor the design, assessment, and integration of complex parts. Dubbed Fusion, the tool is set to target one of the most cruc...